AVALO THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
AVALO THERAPEUTICS, INC. (AVTX) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 3.07 million shares for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-03-23
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-09-30 was 5.24M shares.
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-06-30 was 6.62M shares.
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2024 was 3.07M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|
| 2024-12-31 | 3.07M shares 10-K · filed 2026-03-23 | ||
| 2024-09-30 | 5.24M shares 10-Q · filed 2025-11-06 | 4.05M shares 10-Q · filed 2024-11-07 | |
| 2024-06-30 | 6.62M shares 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |